biotech IPO

IPO initial public offering
Favicon Fierce Biotech

Avalyn brings in $300M from oversized IPO

Avalyn overshot its expectations with a $300 million IPO that the biotech will use to fund late-stage studies of its reformulated respiratory drugs.
James Waldron Apr 30, 2026 3:18am
Asia

Merck, Zai Lab, Kailera-Hengrui—Fierce Pharma Asia

Apr 24, 2026 8:22am
Lung
Favicon Fierce Biotech

Avalyn aims for $182M IPO to fund ph. 3 trials of lung drugs

Apr 24, 2026 7:08am
IPO initial public offering
Favicon Fierce Biotech

Avalyn plans IPO to fund ph. 3 trials of inhaled lung drugs

Apr 9, 2026 4:13am
Asia

Drug tariffs, Takeda, Lilly-Insilico—Fierce Pharma Asia

Apr 3, 2026 7:49am
liver
Favicon Fierce Biotech

BioVie plans $20M IPO for spinout developing liver disease drug

Mar 17, 2026 5:18am